- Home
- IMUX vs DRIO Comparison
IMUX vs DRIO Comparison
Compare IMUX & DRIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMUX | DRIO |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.8M | 82.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IMUX | DRIO |
|---|---|---|
| Price | $0.62 | $12.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $6.00 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 1.2M | 32.1K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,732,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.29 |
| 52 Week Low | $0.56 | $5.94 |
| 52 Week High | $1.39 | $31.00 |
Technical Indicators
Market Signals| Indicator | IMUX | DRIO |
|---|---|---|
| Relative Strength Index (RSI) | 34.77 | 45.63 |
| Support Level | $0.66 | $11.88 |
| Resistance Level | $0.70 | $13.32 |
| Average True Range (ATR) | 0.04 | 0.75 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 5.75 | 35.10 |
Price Performance
Historical ComparisonAbout IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.